JPRN-jRCT1080222732未知Unknown
Specific post-marketing surveillance of pazufloxacin (Pasil) Clinical efficacy and safety of pazufloxacin administered at a dose of 1,000 mg twice daily
Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)0 个研究点目标入组 300 人开始时间: 2015年1月29日最近更新:
试验速览
- 阶段
- Unknown
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Target disease: sepsis, severe or intractable respiratory tract infections (pneumonia, secondary infection of chronic respiratory diseases), or the pneumonia caused by Streptococcus pneumoniae
- •2. Age: 15 years of age and older
- •3. Gender : Both
- •4. Patients administered at a dose of 1,000 mg twice daily
排除标准
- •1. Patients in whom drug efficacy of pazufloxacin (Pasil) was difficult to assess
研究者
相似试验
未知
Unknown
Post-marketing surveillance of administration of botulinum toxin type B(NerBloc)-investigation of the clinical condition in patients with changing from botulinum toxin type Acervical dystoniaJPRN-jRCT1080222128Eisai Co., Ltd.150
已完成
Unknown
Post-marketing surveillance of administration of botulinum toxin type B(NerBloc)-Investigation of the clinical condition and safety in patients with cervical dystoniacervical dystoniaJPRN-jRCT1080222127Eisai Co., Ltd.
未知
Unknown
Specific post-marketing surveillance of garenoxacin (Geninax)JPRN-jRCT1080222731Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)20
已完成
不适用
Non-Interventional Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® IVSerious Fungal InfectionsNCT01073618Pfizer692
尚未招募
4 期
se of palsinuron capsules in sciatica related leg paiCTRI/2024/04/065948S. G. Phyto Pharma Pvt. Ltd